31st Mar 2016 07:00
PuriCore plc
("PuriCore" or the "Company")
Notice of AGM
31 March 2016 - PuriCore plc (AIM: PURI), announces that the 2016 Annual General Meeting will be held at the offices of CMS Cameron McKenna LLP, Cannon Place, 78 Cannon Street, EC4N 6AF London on 16 June 2016 at 10:00 a.m. (GMT). The 2016 Notice of Annual General Meeting and Form of Proxy will be available today on the PuriCore website at www.puricore.com and are today being posted to shareholders.
-Ends-
Enquiries:
PuriCore plc | +44 (0) 20 3727 1000 |
| |
Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer | |||
| |||
FTI Consulting | +44 (0) 20 3727 1000 |
| |
Simon Conway / Mo Noonan / Victoria Foster Mitchell |
| ||
| |||
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
| |
Aubrey Powell / Jen Boorer / Tom Smale |
| ||
About PuriCore
PuriCore is an emerging specialty biopharmaceutical company focused on developing novel immunomodulatory therapies, based on its proprietary hypochlorous acid platform technology. The Company has initiated a drug development program based upon its proprietary technology and formulations at high concentrations. The Company believes their formulations have novel immunomodulatory activity with potential application for the treatment of diseases in a number of therapeutic areas such as Dermatology and Ophthalmology, including potential rare disease indications. Currently, the Company serves the Supermarket Retail sector and Wound Care market (as a medical device) utilizing different formulations. For more information, visit www.puricore.com.
Related Shares:
RLM.L